Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Next Previous
Trial Profile

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 108 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Cytonics Corporation

Most Recent Events

  • 30 Jun 2026 According to Cytonics Corporation media release,, company announced completion of the Clinical Study Report (CSR) for first-in-human Phase I clinical trial evaluating CYT-108 in patients suffering from osteoarthritis of the knee.
  • 26 Dec 2025 Actual primary completion date is 15 Mar 2025.
  • 01 Apr 2025 According to Cytonics Corporation media release, Phase 1 is now complete, and the team is focused on cleaning and locking the database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top